VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: A study by the non-Hodgkin's Lymphoma Co- operative Study Group

Gino Santini, Paolo Coser, Angela Marina Congiu, Luigi Salvagno, Carmino De Souza, Mario Roberto Sertoli, Attilio Olivieri, Teodoro Chisesi, Alessandra Rubagotti, Mauro Truini, Antonio Contu, Adolfo Porcellini, Gino Zambaldi, Sandro Nati, Gennaro Marino, Vittorio Rizzoli

Research output: Contribution to journalArticle

Abstract

Background and Objectives. Sequential treatment with the addition of high-dose therapy (HDT) and peripheral blood progenitor cell (PBPC) rescue has been reported to be active as front-line therapy in aggressive non- Hodgkin's lymphoma (NHL) with bone marrow (BM) involvement. We designed an intensive sequential therapy as front-line therapy in this subset of patients and conducted a phase II study. Design and Methods. Patients with aggressive non-Hodgkin's lymphoma and BM involvement at diagnosis received 8 weeks of VACOP-B chemotherapy as induction therapy. The second phase included high- dose cyclophosphamide (HDCY) (7 g/m2) with granulocyte colony-stimulating factor (G-CSF) followed by leukaphereses. The third phase included HDT according to the BEAM protocol or melphalan (140 mg/m2) plus total body irradiation (8 Gy in a single dose). Results. Forty patients were included in the study. According to the intention-to-treat, after VACOP-B, 11 (27.5%) and 22 (55%) patients achieved complete remission (CR) and partial remission (PR), respectively. Thirty-four received HDCY. After HDCY, 18 patients (45%) were in CR and 13 (32.5%) in PR. Twenty-nine underwent HDT plus peripheral blood cell rescue (PBPC) rescue. At the completion of treatment 29 patients (72.5%) were in CR, and 3 patients (7.5%) in PR. The actuarial 3-year overall survival, disease free survival and failure free survival are 48%, 55% and 40%, respectively. Overall severe toxicity was 7.5%. Interpretation and Conclusions. This phase II study suggests that the intensified treatment described is feasible and active in aggressive NHL with BM involvement. A randomized trial is now underway to test this approach. (C) 2000, Ferrata Storti Foundation.

Original languageEnglish
Pages (from-to)160-166
Number of pages7
JournalHaematologica
Volume85
Issue number2
Publication statusPublished - Feb 2000

Keywords

  • Aggressive non-Hodgkin's lymphoma
  • Bone marrow involvement
  • High-dose therapy

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: A study by the non-Hodgkin's Lymphoma Co- operative Study Group'. Together they form a unique fingerprint.

  • Cite this

    Santini, G., Coser, P., Congiu, A. M., Salvagno, L., De Souza, C., Sertoli, M. R., Olivieri, A., Chisesi, T., Rubagotti, A., Truini, M., Contu, A., Porcellini, A., Zambaldi, G., Nati, S., Marino, G., & Rizzoli, V. (2000). VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: A study by the non-Hodgkin's Lymphoma Co- operative Study Group. Haematologica, 85(2), 160-166.